newsfilter
← Latest News
GlobeNewswire·

Abivax announces trading resumption of its ordinary shares on Euronext Paris

  • Abivax resumed trading of its ordinary shares on Euronext Paris at 3:30 p.m. CEST on July 1, 2026.
  • Trading was halted earlier that day at 9:00 a.m. CEST to confirm investor allocations & announce pricing for a public offering of American Depositary Shares in the United States.
  • The American Depositary Shares represent one ordinary share each with a nominal value of €0.01 per share.
  • Abivax is a clinical-stage biotechnology company based in France & the United States focused on stabilizing immune responses in chronic inflammatory diseases.
  • The company's lead drug candidate, obefazimod (ABX464), is currently in Phase 3 clinical trials for moderately to severely active ulcerative colitis.